ResMed| insider trading
Every open-market purchase and sale by ResMed|'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following ResMed|’s insiders pay?
From February 11, 2010 to August 19, 2025, 23 insiders reported 1 open-market purchase and 188 sales not made under a pre-set plan in ResMed|. Twelve months after each purchase was reported, the shares were −6.0% against the S&P 500 on average (median −6.0%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −1.4% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into.
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Sandercock Brett | Chief Financial Officer | 0 | — | — | 28 | −5.0% (28) | November 29, 2023 |
| Darkin Donald | Pres. Global Innovation and Op | 0 | — | — | 15 | −1.3% (15) | November 13, 2015 |
| Roberts Christopher G | Director | 0 | — | — | 15 | −1.5% (15) | February 24, 2017 |
| Farrell Michael J. | Chief Executive Officer | 0 | — | — | 13 | −4.4% (13) | November 27, 2024 |
| Reiser Anne | President - ResMed Europe | 0 | — | — | 13 | −2.7% (13) | March 2, 2016 |
| Wareham John P | Director | 0 | — | — | 13 | +2.3% (13) | November 5, 2019 |
| Farrell Peter C | Chairman of the Board | 0 | — | — | 11 | −2.7% (11) | February 23, 2024 |
| Douglas Robert Andrew | President and COO ResMed Inc. | 0 | — | — | 10 | +2.7% (10) | November 20, 2019 |
| Pace Gary W | Director | 0 | — | — | 9 | +7.4% (9) | May 10, 2018 |
| Sulpizio Richard | Director | 0 | — | — | 9 | +7.3% (9) | June 1, 2018 |
| Taylor Ronald R | Director | 1 | −6.0% (1) | 0% | 8 | −5.8% (8) | February 22, 2021 |
| Gallahue Kieran | Chief Executive Officer | 0 | — | — | 8 | −20.8% (8) | January 7, 2011 |
| Quinn Michael A | Director | 0 | — | — | 7 | +6.0% (7) | August 30, 2013 |
| Pendarvis David | Chief Administrative Officer | 0 | — | — | 6 | −6.5% (6) | February 13, 2014 |
| Mchale Richard | President, RC Business | 0 | — | — | 5 | +16.1% (5) | February 12, 2020 |
| Hollingshead James | President, Sleep Business | 0 | — | — | 4 | +14.4% (4) | November 18, 2019 |
| Leong Justin | Chief Product Officer | 0 | — | — | 4 | −13.9% (4) | November 25, 2024 |
| Jacobsen Stein | President - Europe | 0 | — | — | 3 | +3.5% (3) | November 28, 2011 |
| Burt Carol | Director | 0 | — | — | 2 | +2.1% (2) | November 23, 2021 |
| Drexler Karen | Director | 0 | — | — | 2 | −19.6% (2) | April 30, 2024 |
| De Witte Jan | Director | 0 | — | — | 1 | +1.8% (1) | May 17, 2024 |
| Hernandez John | Director | 0 | — | — | 1 | −40.4% (1) | August 19, 2025 |
| Sodhi Rajwant | President, SaaS Business | 0 | — | — | 1 | +48.6% (1) | February 27, 2019 |
When several insiders traded ResMed|
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of ResMed| in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 13 selling crowds, −0.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 30, 2022 | 4 selling | −3.9% | −9.6% | −44.4% |
| November 29, 2019 | 5 selling | +14.7% | +8.2% | +23.9% |
| November 30, 2018 | 3 selling | −10.8% | 0.0% | +20.9% |
| January 31, 2018 | 4 selling | +1.7% | +6.4% | −3.4% |
| August 31, 2016 | 5 selling | −9.2% | −1.2% | +2.5% |
| March 31, 2016 | 4 selling | +6.8% | +6.6% | +8.9% |
| November 30, 2015 | 3 selling | +0.7% | −1.5% | −1.7% |
| September 30, 2014 | 3 selling | +9.8% | +40.9% | +6.3% |
| September 30, 2013 | 3 selling | −20.2% | −26.6% | −24.3% |
| November 30, 2011 | 3 selling | +4.8% | +13.7% | +41.9% |
| June 30, 2011 | 4 selling | +5.9% | −14.9% | −4.5% |
| September 30, 2010 | 3 selling | −2.8% | −25.9% | −14.8% |